Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vemurafenib.

Claus Garbe1, Thomas K Eigentler2

  • 1Division of Dermatooncology, Department of Dermatology, University Medical Centre, Liebermeisterstr. 25, 72074, Tuebingen, Germany. claus.garbe@med.uni-tuebingen.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

British journal of cancer·2026
Same author

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal for immunotherapy of cancer·2026
Same author

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Vemurafenib effectively targets BRAF V600E mutations in melanoma, showing significant tumor regressions and improved survival. However, resistance and secondary skin cancers remain challenges, necessitating further research into combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF V600E mutations activate the MAPK pathway in ~40% of melanoma patients, driving proliferation and inhibiting cell death.
  • This mutation leads to continuous signaling, promoting tumor growth and resistance to apoptosis.

Purpose of the Study:

  • To evaluate vemurafenib, a BRAF V600E inhibitor, for its efficacy and safety in treating metastatic melanoma.
  • To explore vemurafenib's potential in other BRAF-mutated cancers and investigate combination strategies.

Main Methods:

  • Vemurafenib selectively inhibits the ATP-binding site of mutated BRAF V600E kinase.
  • Preclinical studies in animal models and Phase I-III clinical trials in melanoma patients with BRAF V600E mutations were conducted.
Keywords:
BRAF inhibitorBRAF mutationMelanomaVemurafenib

Related Experiment Videos

Main Results:

  • Vemurafenib demonstrated high objective response rates (50-80%) and prolonged progression-free survival (7 months vs. 2 months) and overall survival (14 months vs. 9 months).
  • Tumor regressions were observed in BRAF V600E-mutated models; however, resistance developed in most patients, and 25% developed keratoacanthomas.

Conclusions:

  • Vemurafenib is an effective targeted therapy for BRAF V600E-mutated melanoma, offering significant clinical benefit.
  • Addressing vemurafenib resistance and managing side effects are crucial; combination therapies hold promise for enhanced therapeutic potential.